3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Cyclophosphamide
3
fludarabine
2
Paclitaxel
2
Carboplatin
2
Bevacizumab
2
trastuzumab deruxtecan
1
pembrolizumab
1
olaparib
1
niraparib
1
mirvetuximab soravtansine
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
Tinzaparin
1
Propranolol
1
Palliative Care
1
Nivolumab
1
Neoadjuvant Therapy
1
Music Therapy
1
Losartan
1
Indocyanine Green
1
GEN-1
1
Etodolac
1
E7777 fusion protein
1
Clarithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.